PCSK9抑制剂的研究进展
摘要
关键词
全文:
PDF参考
[1] Seidah NG, Benjannet S, Wickham L,et al. The secretory proprotein convertaseneural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuro-nal differentiation.[J].Proc Natl Acad Sci U S A.2003,2,100(3):928-933.[2] Weir HK, Anderson RN, Coleman King SM,et al. Heart Disease and Cancer41Deaths-Trends and Projections in the United States, 1969-2020.[J].Prev ChronicDis.2016,11,13:E157[3] Budha NR, Leabman M,et al. Modeling and Simulation to Support Phase 2 DoseSelection for RG7652, a Fully Human Monoclonal Antibody Against ProproteinConvertase Subtilisin/Kexin Type 9.[J].AAPS.2015,6,17(4):881-890[4] Bonaca MP, Nault P,et al. Low-Density Lipoprotein Cholesterol Lowering WithEvolocumab and Outcomes in Patients With Peripheral Artery Disease: InsightsFrom the FOURIER Trial(Further Cardiovascular Outcomes Research WithPCSK9 Inhibition in Subjects With Elevated Risk). [J]. Circulation. 2018,01,137(4):338-350.[5] Gaudet D,Watts GF,et al. Effect of Alirocumab on Lipoprotein(a) Over≥1.5 Years (from the Phase 3 ODYSSEY Program).[J]. J Am Cardiol. 2017,01, 119(1):40-46.[6] Khan AR, Bavishi C,et al. Increased Risk of Adverse Neurocognitive OutcomesWith Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.[J]. Circ Cardiova-sc Qual Outcomes.2017,01,10(1).
DOI: http://dx.doi.org/10.12361/2661-3603-05-20-147866
Refbacks
- 当前没有refback。